Teillac P, Peyret C, Leroy M, Najean Y, Le Duc A
Service d'Urologie, Hôpital Saint-Louis, Paris.
Ann Urol (Paris). 1988;22(3):193-6.
Prostate-specific antigen (PSA), like prostate acid phosphatase (PAP), are prostate tissue markers that are useful in prostate disorders. Increased PSA levels are often seen in carcinomas of the prostate, but have also been reported in benign inflammatory disorders of the prostate. We therefore studied PSA levels in 600 patients aged 22 to 89 years to evaluate the usefulness of this marker in prostate disorders. The 600 patients were divided into four groups: 120 normal subjects, 180 patients with carcinoma of organs other than the prostate, 75 patients with carcinoma of the prostate, and 225 patients with benign hypertrophy of the prostate.
a significant difference in PSA levels was found between carcinomas and adenomas of the prostate, as well as between stage A carcinomas and adenomas of the prostate. Conversely, non significant difference was evidenced between stage A carcinomas and benign prostatic hypertrophy with inflammation. Rather than a specific marker for cancer, PSA indicates the presence of active prostatic disease, other investigations being necessary to determine whether this disease is malignant. PSA remains extremely useful for monitoring prostate carcinoma patients, especially following radical prostatectomy.
前列腺特异性抗原（PSA）与前列腺酸性磷酸酶（PAP）一样，都是前列腺组织标志物，对前列腺疾病有诊断价值。前列腺癌患者常出现PSA水平升高，不过前列腺良性炎症性疾病患者中也有PSA水平升高的报道。因此，我们对600名年龄在22至89岁之间的患者进行了PSA水平研究，以评估该标志物在前列腺疾病中的诊断价值。这600名患者被分为四组：120名正常受试者、180名非前列腺器官癌患者、75名前列腺癌患者以及225名前列腺良性增生患者。
前列腺癌与腺瘤之间以及A期前列腺癌与腺瘤之间的PSA水平存在显著差异。相反，A期前列腺癌与伴有炎症的前列腺良性增生之间未发现显著差异。PSA并非癌症的特异性标志物，而是提示存在活动性前列腺疾病，要确定该疾病是否为恶性还需进行其他检查。PSA对于监测前列腺癌患者，尤其是在根治性前列腺切除术后，仍然极为有用。
